New Delhi, Dec. 10 -- Cipla Limited on Wednesday announced the launch of Yurpeak (tirzepatide), a once-weekly injectable therapy for the management of obesity and type 2 diabetes mellitus (T2DM) -- two of the country's most pressing health challenges, a press release said.

Cipla has the rights to distribute and promote Yurpeak(R)-- the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval. Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide(GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at...